Roche Holding AG (OTCMKTS:RHHBY – Get Free Report) has earned an average rating of “Hold” from the eleven ratings firms that are currently covering the company, MarketBeat reports. One equities research analyst has rated the stock with a sell recommendation, five have assigned a hold recommendation and five have issued a buy recommendation on the company. The average 12-month price target among brokerages that have updated their coverage on the stock in the last year is $60.00.
Several brokerages recently commented on RHHBY. HSBC downgraded Roche from a “buy” rating to a “hold” rating in a research note on Monday, July 6th. Zacks Research cut Roche from a “hold” rating to a “strong sell” rating in a research note on Tuesday, July 14th. Finally, Morgan Stanley upgraded Roche from an “equal weight” rating to an “overweight” rating and set a $63.00 price target for the company in a report on Friday, August 7th.
Check Out Our Latest Stock Report on RHHBY
Institutional Trading of Roche
Roche Price Performance
Shares of OTCMKTS RHHBY opened at $58.10 on Monday. Roche has a twelve month low of $39.50 and a twelve month high of $60.85. The company has a debt-to-equity ratio of 0.72, a current ratio of 1.38 and a quick ratio of 1.12. The company’s fifty day moving average is $53.30 and its 200-day moving average is $52.93.
Roche Company Profile
Roche Holding AG is a Swiss multinational healthcare company headquartered in Basel, founded in 1896 by Fritz Hoffmann?La Roche. The company operates primarily through two complementary divisions — Pharmaceuticals and Diagnostics — and is known for integrating drug development with diagnostic capabilities to advance personalized healthcare. In the United States and other international markets, shares trade as American Depositary Receipts under the ticker RHHBY (OTCMKTS:RHHBY).
In pharmaceuticals, Roche focuses on developing and commercializing prescription medicines across therapeutic areas including oncology, immunology, infectious diseases and neuroscience, with a notable emphasis on targeted biologics and personalized therapies.
Featured Stories
- Five stocks we like better than Roche
- VIG, VYM, and VYMI: Which Vanguard Dividend ETF Is Right for You?
- 3 Closed-End Funds to Maximize Dividend Payments
- Rocket Lab’s Sell-Off Is Fading—Is It Finally Safe to Buy?
- $27 Billion in Buybacks: 3 Stocks Betting Their Strong Runs Aren’t Over
Receive News & Ratings for Roche Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roche and related companies with MarketBeat.com's FREE daily email newsletter.
